The US plans to put a 100% tariff on imported generic drugs from August 2028, rising to 200% a year later. Generics fill more than 90% of US prescriptions, and most are made abroad, largely in India. The tariff is not yet law: a Commerce Department review due by April 2027 is the route to formal action, and a separate executive order is already stocking a reserve of API, with a preference for US-made ingredients.
US generics tariffs: latest updates
- Sep 23, 2026: Commerce confirmed that the Section 232 pharmaceutical tariffs do not currently apply to generics or their ingredients.
- Sep 8, 2026: PwC estimated the plan could raise about $27 billion a year in duties from August 2028 and $54 billion from August 2029 if sourcing stays the same.
- Jul 21, 2026: The President announced on social media a 0% tariff on imported generics until July 31, 2028, then 100% from August 1, 2028 and 200% from August 1, 2029.
- Apr 2, 2026: Proclamation 11020 put Section 232 tariffs on patented drugs, exempted generics, and gave Commerce one year to report on whether to act on generic imports.
US generics tariffs at a glance
| Region | United States |
| Instrument | Section 232 of the Trade Expansion Act of 1962, through the Commerce generics review ordered in Proclamation 11020 |
| Announced rates | 0% to July 31, 2028; 100% from August 1, 2028; 200% from August 1, 2029 |
| Legal status | Announced only; no implementing proclamation yet |
| Key date | Commerce generics report due by April 2, 2027; 100% rate from August 1, 2028 |
| Import value | About $27 billion a year of generic imports (PwC) |
| Companion policy | Strategic API Reserve (SAPIR), Executive Order 14336, in force since August 2025 |
| Most exposed | Generics makers in India and China, their API suppliers, and US distributors |
| Source | Presidential announcement, July 21, 2026 (no formal text yet) |
| PharmaSource Score | 270 (rank 8) Impact 9, Reach 6, Likelihood 5 Download the PharmaSource Regulatory Radar |
What the US generics tariffs are
When the US put Section 232 tariffs on patented drugs in April 2026, it left generics out. Cheap generics keep US drug spending down, and nearly 70% of them come from abroad. The July announcement set a long runway instead: two tariff-free years for generics makers to build US plants, then a 100% tariff and, a year later, 200%.
The policy works through five levers:
- Tariff cliff: Rates jump from 0% to 100% in August 2028 and to 200% in August 2029.
- Onshoring relief: Generics makers that build US plants and equipment may qualify for mitigation, though no details have been published.
- Commerce review: The generics report due by April 2, 2027 sets the legal basis, product scope and any exemptions.
- Country deals: The February US-India framework promises India “negotiated outcomes” on generic pharmaceuticals and ingredients, and Taiwan’s January deal removes tariffs on its generics.
- API reserve: Executive Order 14336 directs HHS to buy a six-month supply of API for about 26 critical drugs, preferring US-made ingredients.
Where the US generics tariffs stand
- August 13, 2025: Executive Order 14336 orders the Strategic API Reserve filled.
- February 2026: The US-India interim framework promises India negotiated outcomes on generics.
- April 2, 2026: Proclamation 11020 exempts generics and starts the Commerce review.
- July 21, 2026: The President announces the generics tariff schedule.
- September 23, 2026: Commerce confirms generics remain outside the tariffs for now.
The announcement came as a surprise. Brookings senior fellow Marta Wosińska told CDMO Live Americas that the post caught people off guard, “including apparently in the White House,” and she expects news on generics and biosimilars in April, when the Commerce report is due. Nothing formal has followed the post so far.
How the Strategic API Reserve (SAPIR) works
The Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) is the supply-side half of Washington’s generics policy. The tariff makes imported generics dearer; SAPIR stockpiles the ingredients for essential medicines and favors US-made API. The reserve dates from 2020, but the August 2025 executive order said it remained “nearly empty.”
- What it buys: A six-month supply of API for about 26 drugs that HHS judges “vital to national health and security.”
- Who runs it: HHS’s Administration for Strategic Preparedness and Response (ASPR), which readies the repository and costs a proposal for a second one.
- Domestic preference: The order favors US-made API, since only about 10% of API by volume for US medicines is made in the US.
- Funding: Purchases depend on appropriations, and the administration has announced no major new money for onshoring API production.
For API makers and CDMOs, SAPIR is a small buyer with a clear signal: steady government demand for US-made ingredients, alongside a tariff that would make imported ones more expensive.
What the US generics tariffs mean for manufacturing and outsourcing
Generics run on thin margins, and US reimbursement rules limit how much of a tariff companies can pass on. Wosińska argued that Medicaid inflation rebates and 340B rules block that pass-through, and that CDMOs offer little relief in solid oral dose, where generics makers buy capacity on the spot market without committed volumes. The exposure differs by company:
- Indian generics makers: Indian companies supply nearly 50% of US generics. Teneo’s Arpit Chaturvedi expects them to lobby for exemptions, speed up FDA filings and turn to US contract manufacturing.
- API suppliers: China dominates key generic APIs, and one report suggests the tariff would cover ingredients as well as finished doses.
- US CDMOs: Commerce has said tech transfer to a US CDMO counts as onshoring under the branded tariff. If generics follow the same rule, US capacity in sterile injectables and oral solids gains value.
- Sponsors with US product: Companies with marketed product from India, Israel or Singapore face the full rate and are the most likely to move, Wosińska said.
- US API makers: SAPIR purchases give them a small but steady government buyer.
Investment has not kept pace with the rhetoric. PharmaSource tracking shows CDMOs disclosed nearly $18.5 billion of US capex in 2025, but only $3.9 billion worldwide in the first half of 2026. For outsourcing leaders, the practical step is to map every US generic by country of finished dose and API, price a 100% scenario, and open talks now with US CDMOs that have spare solid-dose or sterile capacity.
Why supporters back the US generics tariffs
“Only about 10 percent of the APIs by volume … are made here.”
Executive Order 14336, August 13, 2025
- Supply security: Supporters argue that dependence on India and China for basic medicines is a national security risk that shortages and the pandemic exposed.
- A long runway: Two tariff-free years give companies time to build or contract US capacity before any duty applies.
- Leverage in trade talks: The threat gives Washington a bargaining chip with India and other generics exporters.
- Demand for US API: The White House argues that government purchases for the reserve can encourage more domestic API production.
Criticisms of the US generics tariffs
“You either will have shortages, or you’re going to push manufacturers closer towards China.”
Marta Wosińska, Senior Fellow, Brookings Institution, speaking at CDMO Live Americas 2026
- Shortages: Generics makers cannot absorb a 100% duty, so some will drop products. Patient groups warn of higher prices and worse shortages.
- The math may not change: Deborah Elms of the Hinrich Foundation said she is “not sure that even a potential 200% tariff will change the fundamental math,” because most inputs would still be imported.
- Market failures go unaddressed: The Association for Accessible Medicines and the Indian Pharmaceutical Alliance argue that purchasing and reimbursement problems, not tariffs, keep generics production offshore.
- Mixed signals: PBOA president Gil Roth called the Washington agenda on drug prices and domestic manufacturing “contradictory.”
- No detail: Two years before the cliff, companies still do not know which products, ingredients or countries will be covered.
What’s next for the US generics tariffs
- By April 2, 2027: Commerce reports on generic imports. Watch for product scope, API coverage and onshoring credits.
- Proclamation: A presidential proclamation would set the legal rates, exemptions and country terms.
- Trade deals: India’s “negotiated outcomes” on generics remain to be defined.
- August 1, 2028: The 100% rate applies, rising to 200% on August 1, 2029.
- Our score: Impact 9, Reach 6, Likelihood 5, giving 270 and rank 8. A 100% duty would force supply moves, but nothing is formal yet; Likelihood rises if the Commerce report backs action.
Related articles
- Urban Wastewater Treatment Directive: The Polluter-Pays Levy Testing EU Generics (Nov 21, 2026)
- Section 232 Pharma Tariffs Explained: What They Are and Their Impact on Pharma Manufacturing (Nov 15, 2026)
- How Section 232 Tariffs and FDA Upheaval Are Reshaping US Contract Manufacturing (Nov 9, 2026)
- Tariffs, FDA Chaos, and BioSecure in Limbo: How CDMOs Should Operate Under Uncertainty (Jun 28, 2026)
- All coverage: Generics Tariffs